ArticleBMC veterinary research2025
Development of a monoclonal antibody-based competitive enzyme-linked immunosorbent assay for detection of antibodies against duck adenovirus 3.
Article in BMC veterinary research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Innovations, Applications, and Future Trends in Veterinary Diagnostic Technologies.Transboundary and emerging diseases · 2026Review
- Detection of duck adenovirus 3 using RAA-CRISPR/Cas12a based lateral flow dipstick method.Frontiers in microbiology · 2026Article
- Development of a Blocking ELISA for Detection of Serum Neutralizing Antibodies Against Duck Adenovirus Type 3.Microorganisms · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundDuck adenovirus 3 (DAdV-3), the emerging pathogen of a disease characterized by swelling and hemorrhage in liver and kidney, is widely distributed in China, resulting in serious economic losses to the duck farms. However, no vaccine is commercially available for the prevention of the disease. Thus, a precise and reliable diagnosis is of great value for the implementation of control measure to limit the spread of DAdV-3 infection. In this study, a competitive enzyme-linked immunosorbent assay (c-ELISA) was developed for detection of antibodies against DAdV-3.
resultsIn the c-ELISA, a monoclonal antibody (mAb) 3D9, which was specific to Fiber-2 protein of DAdV-3, was labeled with horseradish peroxidase (HRP) and then used as secondary antibody. The cut-off value of the c-ELISA was determined as 18% using 48 clinical negative duck sera. The preliminary concordance evaluation based on 24 duck sera revealed that the results of the c-ELISA were highly consistent with those of indirect immunofluorescence assay (IFA). The cross-reactivity assessment showed that the c-ELISA only reacted with the positive sera against DAdV-3, but not with positive sera against other duck-associated viruses tested. The coefficients of variation of intra-batch and inter-batch assays were all below 10%, suggesting a good repeatability of the c-ELISA. Moreover, 133 duck sera from animal experiments in our laboratory were detected by c-ELISA and indirect ELISA. The results showed that the coincidence rate between the two assays was 90.98% (121/133) and the Kappa value was 0.815, revealing almost perfect agreement of the two assays.
conclusionsIn summary, the c-ELISA developed here was specific, repeatable and reliable. The minimal cross-reactivity and independence of species-specific enzyme-conjugated secondary antibody made the c-ELISA a promising tool for the clinical diagnosis, serological epidemiological investigation, and evaluation of vaccine immunogenicity to control the disease caused by the infection of DAdV-3.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.